Journal of Gastroenterology

, Volume 52, Issue 4, pp 419–431

Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma

  • Wenhui Wang
  • Qiuwei Pan
  • Gwenny M. Fuhler
  • Ron Smits
  • Maikel P. Peppelenbosch
Open Access
Review
  • 1.1k Downloads

Abstract

Hepatitis C virus (HCV) infection is one of the leading causes of hepatocellular carcinoma (HCC) worldwide but the mechanistic basis as to how chronic HCV infection furthers the HCC process remains only poorly understood. Accumulating evidence indicates that HCV core and nonstructural proteins provoke activation of the Wnt/β-catenin signaling pathway, and the evidence supporting a role of Wnt/β-catenin signaling in the onset and progression of HCC is compelling. Convincing molecular explanations as to how expression of viral effectors translates into increased activity of the Wnt/β-catenin signaling machinery are still largely lacking, hampering the design of rational strategies aimed at preventing HCC. Furthermore, how such increased signaling is especially associated with HCC oncogenesis in the context of HCV infection remains obscure as well. Here we review the body of contemporary biomedical knowledge on the role of the Wnt/β-catenin pathway in the progression from chronic hepatitis C to cirrhosis and HCC and explore potential hypotheses as to the mechanisms involved.

Keywords

Hepatocellular carcinoma Wnt/β-catenin signaling Hepatitis C virus 

Abbreviations

APC

Adenomatous polyposis coli

EGFR

Epidermal growth factor receptor

ERK

Extracellular-signal-regulated kinase

FGF

Fibroblast growth factor

FZD

Frizzled

GSK3β

Glycogen synthase kinase 3β

HBV

Hepatitis B virus

HCC

Hepatocellular carcinoma

HCV

Hepatitis C virus

LECT2

Leukocyte-cell-derived chemotaxin 2

MEK

Mitogen-activated protein kinase kinase

MMP

Matrix metalloproteinase

PI3K

Phosphoinositide 3-kinase

RNF43

Ring finger protein 43

SHP-2

Src homology region 2 domain containing phosphatase 2

ZNRF3

Zinc/ring finger protein 3

Introduction

Hepatitis C virus (HCV) is estimated to infect up to 2% of the global population (around 180 million people worldwide) [1], with approximately 3 million to 4 million new infections each year [2, 3]. Following infection, 60–80% of affected individuals eventually develop chronic hepatitis [4]. After around 10 years of infection, 5–10% of these chronically infected patients develop cirrhosis [5]. In addition to the high mortality associated with advanced cirrhosis per se, annually another 2.0–6.6% of cirrhotic patients with HCV infection develop hepatocellular carcinoma (HCC) [6, 7]. Understanding the details as to how HCV infection can promote the HCC process is thus of critical importance for the rational design of novel avenues aimed at the prevention and treatment of HCC.

Distinct from hepatitis B virus (HBV), a DNA virus that can integrate into the human genome and thus directly provoke genomic alterations potentially leading to cancer [8], HCV is a RNA virus lacking a DNA intermediate phase in its life cycle, and therefore its infection of liver cells is not associated with damage to the host genetic material per se [9]. Hence the tumor-promoting potential of HCV derives from indirect interaction with the hepatocyte genome. It thus appears that HCV has specific properties that promote further hepatocyte transformation.

The Wnt/β-catenin pathway is an attractive candidate to mediate the HCV-specific effects leading to hepatocyte oncogenic transformation. Activation of this pathway clearly contributes to hepatocarcinogenesis as indicated by the detection of recurrent genetic mutations of Wnt/β-catenin signaling pathway components in HCC that appear especially frequent in HCV-related tumors. HCV-derived viral proteins appear to be capable of autonomous activation of Wnt/β-catenin signaling, although the underlying molecular mechanisms remain poorly understood. Here we explore potential hypotheses explaining these effects and summarize documented interactions of Wnt/β-catenin signaling components in HCC patients with HCV infection. We propose that the Wnt/β-catenin signaling pathway constitutes a rational target for the prevention and treatment of HCV-associated HCC.

Wnt/β-catenin signaling

Wnt/β-catenin signaling is a pivotal morphogenetic pathway and accordingly is associated with a host of physiological and pathophysiological processes, including embryonic patterning, cell proliferation, cell differentiation, angiogenesis, and especially cancer [10, 11, 12]. Wnt signaling is initiated by binding of Wnt ligands to their cognate receptors. These Wnt ligands are 40-kDa cysteine-rich glycoproteins [13], which following synthesis and primary glycosylation on the endoplasmic reticulum are palmitoylated by Wnt acyltransferase porcupine protein in the Golgi apparatus. Secretion of Wnts then requires evenness interrupted/Wntless/G-protein-coupled receptor 177, which shuttles palmitoylated Wnts to the plasma membrane, where they are released by the cell and initiate autocrine or paracrine signaling. Hitherto, 19 Wnts have been identified in the human genome [14], and because annotation of Homo sapiens DNA is now quite complete, it is unlikely further Wnt paralogues will be discovered. Wnts can provoke different modes of cellular signaling, either mediated by β-catenin or independent of this protein. According to the dependence on β-catenin for provoking cellular effects, Wnts are classified into canonical (β-catenin-dependent) and noncanonical (β-catenin-independent) subgroups [15, 16]. In this review we will focus on the canonical Wnts, as these are most associated with HCC in general and HCV-infection-associated HCC in particular.

Except for several stem cell niches, canonical Wnt/β-catenin signaling is typically not active in tissues of adult individuals [17], despite constitutive production of Wnt ligands. This is a result of the action of a range of Wnt antagonists, such as secreted frizzled (FZD)-related proteins, dickkopf, and Wnt inhibitory factor [18]. In this nonsignaling state, cytosolic β-catenin is continuously phosphorylated at Ser33, Ser37, Thr41, and Ser45 residues located in exon 3 by a multiprotein complex consisting of adenomatous polyposis coli (APC), axin, glycogen synthase kinase 3β (GSK3β), and casein kinase 1. These phosphorylations cause β-catenin to be recognized and polyubiquitinated by β-transducin repeat containing protein, followed by β-catenin degradation in the proteasome [18, 19]. The overall effect is that minimal free cytosolic β-catenin is available for nuclear signaling, and thus Wnt-mediated gene transcription is absent under normal conditions.

On binding of Wnt ligands to a complex consisting of the FZD receptor and coreceptors, which include low-density lipoprotein receptor related protein 5/6, the scaffolding protein disheveled is recruited to the membrane, an event that in turn causes the disassembly of the multiprotein β-catenin destruction complex. This results in rescue of β-catenin from proteasomal degradation and thus the accumulation of β-catenin in the cytoplasm, eventually causing β-catenin translocation to the nucleus [20]. In the nucleus, β-catenin binds transcription factors of the T-cell factor 4 (transcription factor 7, transcription factor 7 like 1, and transcription factor 7 like 2)/lymphoid enhancer binding factor family, triggering transcription of downstream Wnt target genes, including CYCLIND1, AXIN2, MYC, RNF43 (which encodes ring finger protein 43, RNF43), and ZNRF3 (which encodes zinc/ring finger protein 3, ZNRF3) [21, 22]. RNF43 and ZNRF3 are two closely related transmembrane E3 ligases, which remove surface FZD receptors by promoting their endocytosis [23]. This E3 ligase activity is in turn negatively modulated by R-spondins and leucine-rich repeat containing G-protein-coupled receptor 4/5/6, which sequestrate RNF43 and ZNRF3 from FZD receptors by forming a tripartite complex [24]. Hence regulation of Wnt target gene transcription is complex, allowing extensive regulation but also mechanisms leading to deregulation of target gene transcription in pathophysiology.

Further complexity is added by the role of β-catenin in cell–cell adhesion, where it acts, independent of its transcriptional activity, by forming a complex with cadherins and facilitating the formation of cellular junctions between adjacent hepatocytes. The β-catenin captured in these cell-adhesion complexes represents a dynamic pool of β-catenin capable of nuclear signaling following several stimuli. One of these stimuli is β-catenin tyrosine phosphorylation by receptor tyrosine kinases activated by growth factors produced by epithelial and stromal cells. In particular, phosphorylation of the β-catenin residue Tyr654 results in its release from cadherins and an increase in T-cell-factor-mediated transcriptional activity [25, 26, 27, 28]. Furthermore, the adherence pool of β-catenin also appears to be under indirect control of Wnt signaling itself. On activation of canonical Wnt/β-catenin signaling, the suppression of GSK3β leads to the upregulation of SNAIL [29]. As SNAIL is a repressor of the CDH1 gene encoding E-cadherin [30, 31], this will lead to reduced E-cadherin production. Diminished E-cadherin production causes the dissociation of the complex and subsequent internalization of β-catenin and accumulation of β-catenin in the perinuclear endocytic recycling compartment, which promotes translocation to the nucleus to activate Wnt/β-catenin signaling [32, 33]. Hence pathogens can also provoke β-catenin signaling by disrupting intercellular junctions, in addition to direct effects on elements of the Wnt signaling cascade involved in regulating β-catenin-mediated transcription.

Aberrant activation of Wnt/β-catenin signaling during HCC

Important in the context of potential modulation by HCV infection in relation to HCC is that aberrant signal transduction in general and β-catenin signaling in particular is one of the key characteristics of hepatocarcinogenesis [34]. Functional deregulation of Wnt/β-catenin signaling is reported frequently in HCC, strongly suggesting that this pathway is important in this tumor type. Various genetic and molecular alterations have been identified to be pro-oncogenic in a variety of settings, and have as a common denominator that they stabilize β-catenin, thus provoking enhanced transcriptional activity of Wnt target genes. Table 1 summarizes the relative mutation frequency of Wnt/β-catenin signaling elements in HCC patients. From HCC cohorts from different countries, the most prevalent are activating mutations in CTNNB1 (which encodes β-catenin), followed by loss-of-function mutations in AXIN1, AXIN2, and APC. The relative mutation frequencies of these various Wnt/β-catenin signaling elements are different in HCC as compared with other cancers (e.g., sporadic colorectal cancer). The reason that these differences emerge may result from different causes of HCC and thus the type of mutations induced in liver genomes as compared with other sites in the body, but may also derive from the fact that in different organs, optimal cancer-driving Wnt/β-catenin signaling mutations may be substantially different, resulting in selection pressure for different types of mutations [35, 36]. As indicated in Table 1, around 22.1% of HCCs harbor specific gain-of-function mutations of CTNNB1. Missense, insertion, or partial deletions within CTNNB1 exon 3 lead to the generation of a mutant β-catenin preventing the proper phosphorylation of amino acids Ser33, Ser37, Thr41, and Ser45, resulting in compromised degradation and thus stabilization of β-catenin in the cytoplasm. Less frequently, loss-of-function mutation of AXIN1, AXIN2, or APC is found in 3.2%, 0.4%, and 0.2% of HCCs respectively, evidently contrasting with the situation in colorectal cancer, where up to 80% of cancers display mutated APC [36, 37]. Frameshift in or deletion of these genes yields impaired ability of the destruction complex to degrade β-catenin and is thus also associated with enhanced Wnt/β-catenin signaling. Overexpression of upstream ligands or cell surface receptors and reduction of expression of extracellular inhibitors have been reported to stimulate activation of this pathway in HCC as well [38]. Thus at some stage in the progression toward full-blown HCC, acquisition of increased Wnt/β-catenin signaling provides liver cancer cells with a relative advantage over cells not having such mutations. Here we will argue that especially HCV infections create the conditions that allow precarcinogenic cancer cells to exhibit such enhanced Wnt/β-catenin signaling.
Table 1

Genetic mutation in components of the Wnt/β-catenin pathway in hepatocellular carcinoma

References

Patients

Mutant samples

Region

CTNNB1

AXIN1

AXIN2

APC

Rebouissou et al. [39]

373

146 (39%)

NA

NA

NA

France, Spain, Italy

Hirotsu et al. [40]

9

2 (22.2%)

NA

NA

NA

Japan

Schulze et al. [41]

243

95 (37.4%)

27 (11.1%)

3 (1.2%)

4 (1.6%)

France, Italy, Spain

Kan et al. [42]

88

14 (15.9%)

4 (4.5%)

2 (2.3%)

2 (2.3%)

China

Kitao et al. [43]

134

27 (20.1%)

NA

NA

NA

Japan

Ding et al. [44]

156

15 (9.6%)

NA

NA

NA

China

Tornesello et al. [45]

67

10 (14.9%)

NA

NA

NA

Southern Italy

Cleary et al. [46]

87

20 (22.9%)

NA

NA

NA

Canada, USA

Guichard et al. [47]

125

41 (32.8%)

19 (15.2%)

NA

2 (1.6%)

France

Lachenmayer et al. [48]

90

29 (32.2%)

NA

NA

NA

USA, Netherlands, Italy, Spain, Germany

Li et al. [49]

139

28 (20.1%)

NA

NA

NA

USA, Netherlands, China

Cieply et al. [50]

32

9 (28.1%)

NA

NA

NA

USA

Bengochea et al. [38]

62

16 (25.8%)

NA

NA

NA

Thailand, France

Austinat et al. [51]

40

10 (25%)

2 (5%)

NA

NA

Germany

Kim et al. [52]

36

1 (2.8%)

9 (25%)

NA

NA

Korea

Zucman-Rossi et al. [53]

45

18 (40%)

5 (11.1%)

NA

NA

France

Boyault et al. [54]

120

34 (28.3%)

13 (10.8%)

NA

NA

France

Zucman-Rossi et al. [55]

96

12 (12.5%)

NA

NA

NA

France

Park et al. [56]

81

13 (16%)

5 (6.2%)

NA

NA

Korea

Ishizaki et al. [57]

89

10 (11.2%)

13 (14.6)

9 (10.1%)

NA

Japan

Cui et al. [58]

34

15 (44.1%)

NA

NA

NA

China

Edamoto et al. [59]

100

24 (24%)

NA

NA

0

Japan, Switzerland

Taniguchi et al. [60]

73

14 (19.2%)

7 (9.6%)

2 (2.7%)

NA

UK

Wong et al. [61]

60

7 (11.7%)

NA

NA

NA

China

Mao et al. [62]

262

37 (14.1%)

NA

NA

NA

Taiwan

Cui et al. [63]

34

15 (44.1%)

NA

NA

NA

China

Laurent–Puig et al. [64]

137

26 (19%)

12 (8.8%)

NA

NA

France

Devereux et al. [65]

62

5 (8.1%)

NA

NA

NA

China

Hsu et al. [66]

434

57 (13.1%)

NA

NA

NA

Taiwan

Satoh et al. [67]

87

0 (0%)

5 (5.7%)

NA

NA

Japan

Huang et al. [68]

22

9 (41%)

NA

NA

NA

Japan, Switzerland

Legoix et al. [69]

119

21 (17.6%)

NA

NA

NA

France

Terris et al. [70]

73

14 (19.2%)

NA

NA

NA

France

Kondo et al. [71]

38

9 (24%)

NA

NA

NA

Japan

Van Nhieu et al. [72]

35

12 (34.3%)

NA

NA

NA

France

Miyoshi et al. [73]

75

14 (18.7%)

NA

NA

NA

Japan

de La Coste et al. [74]

31

8 (25.8%)

NA

NA

NA

France

Total

3788

837 (22.1%)

121 (3.2%)

16 (0.4%)

8 (0.2%)

 

NA not analyzed

High frequency of CTNNB1 mutation in HCV-related HCC

HCV infection presents a substantial clinical challenge, for which only direct antiviral medication appears to be a suitable solution [75]. If left untreated or not recognized soon enough, persistent HCV infection causes immune-mediated chronic liver damage and compensatory hepatic regeneration by inducing cell proliferation and thus creates a microenvironment permissive for the induction of genetic alterations to the hepatocyte genome [76]. Following HCV infections, genetic abnormalities accumulate relatively slowly during the sequence of chronic hepatitis and increased cirrhosis that finally progresses to HCC. Consequently, the selective growth advantage provided to hepatocytes with a malignant phenotype eventually facilitates the development of phenotypically and genetically heterogeneous HCC [77]. The relatively high frequency of mutations of CTNNB1 (one of the principal proto-oncogenes in HCC development) in HCV-related HCC is especially striking, in the view of the relative absence of such mutations in HBV-related liver cancers but also in the view of their paucity in non-virally-associated HCC (Table 2). Around 26.7% of HCV-related HCCs harbor a CTNNB1 mutation, which is a much higher frequency than that observed in HBV-associated HCC (11.6%) or that observed in total non-virally-associated HCC (21.2%). Furthermore, we noticed that, differently from colorectal cancers, which mainly show Thr41 and Ser45 mutations [36], HCV-related HCC shows a preference for CTNNB1 mutations from Asp32 to Ser37 residues [45, 47, 49, 59, 68, 70, 71] (Fig. 1). Recently, a genotype–phenotype correlation was shown for CTNNB1 mutations, suggesting that activating mutations occurring at the Asp32 to Ser37 residues lead to higher signaling levels than mutations at Thr41 and Ser45 [39]. This may partially explain the preference. It also could be attributable to the mutagenic dose required to induce HCC. Mutations at Ser45 require the selective duplication of the mutated allele as a second activating hit, whereas only one activating hit is required for mutations at Asp32 to Ser37.
Table 2

Comparison of CTNNB1 mutation in subtypes of hepatocellular carcinoma

References

CTNNB1 mutant samples

Mutation type

Amino acid

Region

HCV

HBV

NV

Hirotsu et al. [40]

2/5 (40%)

0/1 (0%)

0/3 (0%)

Missense

Gly34, His36

Japan

Kitao et al. [43]

12/55 (21.8%)

4/34 (11.8%)

11/44 (25%)

NA

NA

Japan

Ding et al. [44]

NA

12/110 (10.9%)

3/46 (6.5%)

Missense

Asp32, Gly34, Ser37, Thr41, Ser45

China

Tornesello et al. [45]

10/57 (17.5%)

0/10 (0%)

NA

Missense

Asp32, Ser33, Gly34 Ile35, Ser37, Ser45

Southern Italy

Kan et al. [42]

NA

12/81 (14.8%)

NA

Missense

Asp32, Ser33, Gly34 Ile35, Ser37, Thr41, Ser45

China

Guichard et al. [47]

8/24 (33.3%)

4/35 (11.4%)

30/80 (37.5%)

Missense

Insertion

Deletion

Asp32, Ser33, Ser37, Thr41,Thr42, Ser45

France

Li et al. [49]

14/45 (31.1%)

6/52 (11.5%)

9/44 (20.5%)

Missense

Deletion

Asp32, Ser33, Gly34, His36, Ser37, Thr41, Ser45, Asn387

USA, Netherlands, China

Bengochea et al. [38]

8/20 (40%)

3/18 (16.7%)

5/24 (20.8%)

Missense

Insertion

Asp32, Ser33, Ser37, Thr41 Ser45

Thailand, France

Kim et al. [52]

0/4 (0%)

0/21 (0%)

1/14 (7.1%)

Missense

Ser33

China

Park et al. [56]

0/6 (0%)

13/78 (16.7%)

NA

Missense

Deletion

Asp32, Ser33, Gly34 Ile35, His36, Ser37, Thr41, Ser45

Korea

Edamoto et al. [59]

16/51 (31.4%)

5/26 (19.2%)

3/23 (13%)

Missense

Asp32, Ser33, His36, Ser37, Thr41, Ser45

Japan, Switzerland

Wong et al. [61]

0/2 (0%)

5/48 (10.4%)

2/10 (20%)

Missense

Deletion

Asp32, Ser33, Gly34 Ile35, Ser37, Thr41, Ser45

China

Hsu et al. [66]

23/92 (25%)

30/323 (9.3%)

4/19 (21.1%)

Missense

Deletion

Asp32, Gly34,

Thr41, Ser45

Taiwan

Huang et al. [68]

9/22 (41%)

NA

NA

Missense

Asp32, Ser33, Ser37,

Thr41, Ser45

Japan, Switzerland

Legoix et al. [69]

7/30 (23.3%)

5/26 (19.2%)

13/64 (20.3%)

Missense

Deletion

Asp32, Ser33, Gly34, Ser37, Thr41, Ser45

France

Terris et al. [70]

2/7 (28.6)

3/14 (21.4)

9/52 (17.3)

Missense

Deletion

Asp32, Ser33, Gly34, Ser37, Ser45

France

Kondo et al. [71]

7/22 (31.8%)

1/8 (12.5%)

1/9 (11.1%)

Missense

Deletion

Asp32, Ser33, Gly34, Ile35, His36, Ser37, Thr41, Ser45

Japan

Total

118/442 (26.7%)

103/885 (11.6%)

91/432 (21.1%)

   

HBV hepatitis B virus, HCV hepatitis C virus, NA not analyzed, NV not viral

Fig. 1

Summary of CTNNB1 exon 3 mutations in hepatitis C virus related hepatocellular carcinoma. The locations of the CTNNB1 mutations reported in 68 tumors from 65 hepatocellular carcinoma patients (one tumor with p.D32_G48del, not shown) are illustrated. N-terminal serine and threonine phosphorylation residues are indicated in bold. Numbers in parentheses are the absolute number of tumors tested with the given mutation

Although CTNNB1 mutation appears to be a late-stage event in the progression to HCC [56], the high rate of CTNNB1 mutations observed may be directly and causally related to the HCV infectious process as in vitro studies show that both acute and chronic HCV infections provoke specifically CTNNB1 mutations in hematological model systems and HCCs [78]. Evidently, clarification of the relationship between infection with a nonintegrating virus and subsequent CTNNB1 mutations may prove exceedingly useful for the design of strategies aimed at preventing HCV-associated HCC.

HCV structural proteins activate Wnt/β-catenin signaling

The HCV genome is a single-stranded positive-sense 9.6-kb RNA molecule, which includes a single open reading frame encoding a polyprotein of approximately 3000 amino acids that following translation is cleaved into ten mature proteins by both host and viral proteases. These proteins are the structural proteins (core, E1 and E2), viroporin p7, and the nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B). The pro-oncogenic pathogenesis of HCV appears mainly mediated by the core protein and two of the nonstructural proteins, NS3 and NS5A [79]. These pro-oncogenic effects appear to depend largely on the potential of these proteins to mediate activation of Wnt/β-catenin signaling.

Core protein

The 21-kDa core protein is the major component of HCV. Despite lacking obvious organelle localization signals in the primary sequence, it is detected not only in the cytosol but also in the Golgi apparatus, in lipid droplets, and in the nucleus [80, 81]. Remarkably, in the latter organelle it serves as a regulator of hepatocyte transcription, facilitating Wnt/β-catenin signaling. This is brought about by upregulation of canonical Wnts, FZD receptor, and low-density lipoprotein receptor related protein 5/6 [82, 83] while concomitantly inhibiting transcription of the Wnt antagonists secreted FZD-related protein 2 and dickkopf 1 [84]. The latter effect is mediated by epigenetic silencing of the promoters involved in core-protein-mediated recruitment of DNA methyltransferase 1 and histone deacetylase 1 to the transcription start site, an effect already detected early in hepatitis infection [84, 85]. In addition, the HCV core protein mediates hypermethylation of the CDH1 (E-cadherin) gene promoter [86]. Reduced production of E-cadherin results in diminished sequestering of β-catenin in β-catenin–E-caherin complexes and thus enhanced activation of Wnt/β-catenin signaling (Fig. 2). Hence the core protein mediates a plethora of molecular events leading to increased Wnt/β-catenin signaling and thus apparently HCV is under substantial selection pressure to provoke Wnt/β-catenin signaling. Potential sources for this selection pressure are a necessity to counteract hepatocyte apoptosis, whereas Wnt/β-catenin signaling driven expansion of the HCV-infected compartment may be involved as well.
Fig. 2

Wnt/β-catenin signaling is activated by hepatitis C virus (HCV) proteins. HCV core protein elevates gene expression of Wnt ligands, frizzled (FZD) receptor, and low-density lipoprotein receptor related protein 5/6 (LRP5/6) but decreases the expression of the Wnt antagonists dickkopf (DKK) and secreted frizzled-related protein (SFRP) by recruiting DNA methyltransferase 1 (DNMT1) and histone deacetylase 1 (HDAC1) to their transcription start sites. In addition, HCV core protein releases β-catenin from the β-catenin–E-cadherin complexes by suppression of the CDH1 gene promoter (which encodes E-cadherin). NS5A protein activates phosphoinositide 3-kinase (PI3K)/Akt signaling, leading to the inactivation of glycogen synthase kinase 3β (GSK3β) and subsequent reduced breakdown of β-catenin, or directly stabilizes β-catenin. The overall effect is the cytoplasmic accumulation of β-catenin and stimulation of downstream transcription

NS5A

The notion that HCV is under selection pressure to counteract apoptosis is further reinforced by observations that NS5A not only functions as a component of the HCV RNA replication complex [87] but also binds to the p85 regulatory subunit of phosphoinositide 3-kinase (PI3K), thus activating the downstream effector serine/threonine kinase Akt [88, 89]. Akt activation provides a powerful antiapoptotic signal and also mediates the inactivation of GSK3β, stabilization of β-catenin, and subsequent stimulation of β-catenin-dependent transcription [90]. In addition, the NS5A protein binds and stabilizes β-catenin directly [91], apparently independent of its effects on Akt and GSK3β [92] (Fig. 2). Thus the multiple stimulatory effects of NS5A on Wnt/β-catenin signaling are also testimony to the selection pressure of HCV to increase hepatocyte Wnt/β-catenin signaling.

More Wnt/β-catenin signaling stimulating effects

The hypotheses that successful HCV infection critically depends on its potential to stimulate Wnt/β-catenin signaling is further supported by observations that, in addition to direct activation, HCV infection leads to elevation of the levels of miR-155 [93] and miR-199a-5p [94], in turn triggering Wnt/β-catenin signaling. MicroRNA miR-155 acts as an oncomiR by targeting the suppressor of the suppressor of cytokine signaling 1 gene (SOCS1) [95], which directly inhibits APC expression, one of the major negative regulators of Wnt/β-catenin signaling [93]. Moreover, both direct and indirect activation by HCV viral proteins may explain the notable dysregulation of Wnt/β-catenin signaling in hepatitis C and the related HCC subclass. Moreover, HCV core, NS3, and NS5A proteins may facilitate further oncogenic transformation of infected hepatocytes [79] by suppression of DNA repair mechanisms, potentially causing CTNNB1 mutations. Support for this idea can be found in the observation that in experimental animals the hepatocarcinogenic nitrosamine diethylnitrosamine provokes cancer by inducing CTNNB1 mutations [96, 97], and thus increased mutagenic pressure through corruption of DNA repair may be preferentially associated with this mutation. Hence the effects on the DNA repair machinery exerted by HCV core, NS3, and NS5A may link increased Wnt/β-catenin signaling mediated by direct effects of these proteins early in infection to mutation-mediated activation of Wnt/β-catenin signaling later in the progression to HCC.

Wnt/β-catenin signaling paves the way for progression of chronic hepatitis C to HCC

Inflammation

The HCV battles with the immune system. Thus negative modulation of inflammatory responses through enhanced Wnt/β-catenin signaling could conceivably provide further selection pressure for HCV to acquire Wnt/β-catenin signaling activating properties. However, the effect of Wnt/β-catenin signaling on hepatocyte immune responses remains controversial. On one hand, Wnt/β-catenin signaling could suppress the immune response by blunting T-cell activation [98, 99], reducing release of tumor necrosis factor [100] or stimulating the production of the chemokine-like chemotactic factor leukocyte-cell-derived chemotaxin 2 (LECT2) and invariant natural killer T cell responses, both of which relay anti-inflammatory response [101]. On the other hand, Wnt/β-catenin signaling triggers inflammatory responses by activating the proinflammatory nuclear factor κB pathway, as evident from experimentation in a hepatocyte-specific APC and LECT2 knockout (Apc−/−Lect2−/−) mouse model [101]. In potential agreement, germline genetic variations in Wnt/β-catenin signaling elements were significantly associated with the risk of inflammation in HCV-infected male patients [102]. Thus the issue as to how HCV-elicited Wnt/β-catenin signaling relates to HCV-provoked inflammation warrants further experimentation.

Fibrosis to cirrhosis and HCC development

Chronic inflammation evoked by HCV infection may culminate in liver fibrosis. Such fibrosis progresses gradually and disrupts liver physical structure and function over the course of several decades, finally resulting in fatal diseases such as cirrhosis and HCC [103]. Given HCV-stimulation of Wnt/β-catenin signaling probably evolved to support the early phases of viral infection, emerging data suggest that Wnt/β-catenin signaling activated by HCV participates in the pathogenesis of liver fibrosis as well [102, 103], mainly by enhancing hepatic stellate cell activation and survival [104]. The subsequent progression toward full-blown HCC is a complex process involving many various signaling pathways, but especially cross talk between epidermal growth factor receptor (EGFR) signaling and fibroblast growth factor (FGF) receptor signaling and aberrant activation of Wnt/β-catenin signaling appears important here.

The EGFR pathway controls a variety of signals ranging from cell proliferation, cell motility, and apoptosis decrease to epithelial–mesenchymal transition, upregulation of matrix metalloproteinases (MMPs), and even stem cell maintenance [105]. EGFR is highly expressed in the adult liver [106] and plays an essential role in the G1–S phase transition for hepatocyte proliferation [107]. EGFR pathway dysregulation has been reported in 60–80% of HCC patients [108], and is associated with the late stages and the degree of tumor differentiation [109, 110]. EGFR favors HCV entry through co-internalization of an HCV–CD81–EGFR complex following binding of EGFR ligands to the receptor and subsequent endocytosis [111, 112]. Following clathrin-mediated endocytosis of EGFR, EGFR is routed for eventual intracellular degradation [113]. The viral NS5A protein, however, perturbs EGFR trafficking and degradation, increasing EGFR signaling and contributing to HCV-mediated HCC development [114]. Binding of Wnt1 and Wnt5a to FZD transactivates EGFR signaling by MMP-mediated release of soluble EGFR ligands, such as transforming growth factor α [115]. Activated β-catenin might form heterodimers with EGFR to enhance EGFR pathway activation [116]. Conversely, EGFR signaling contributes to Wnt/β-catenin signaling in various ways. Firstly, EGFR can directly induce tyrosine phosphorylation of β-catenin at residue Tyr654, thereby decreasing the binding with cell-adhesion complexes and releasing it for nuclear signaling [104, 117]. This phenomenon has been observed for a large number of growth factors signaling through receptor tyrosine kinases, such as hepatocyte growth factor and FGFs that are produced in excess by the cirrhotic tissue adjacent to tumor tissue [28, 118, 119, 120]. Secondly, EGFR stimulates the PI3K/Akt and Ras/Raf/mitogen-activated protein kinase kinase (MEK)/extracellular-signal-regulated kinase (ERK) cascades that both can promote β-catenin signaling through inhibition of GSK3β activity [121, 122, 123, 124, 125] (Fig. 3). Thus HCV-mediated activation of Wnt/β-catenin signaling may initiate a vicious interaction between EGFR and Wnt signaling, promoting potentially pro-oncogenic hepatocyte proliferation.
Fig. 3

Cross talk of the Wnt/β-catenin pathway with the epidermal growth factor receptor (EGFR) and fibroblast growth factor (FGF) pathways in hepatitis C virus (HCV)-related hepatocellular carcinoma. HCV promotes Wnt signaling as well as the EGFR and FGF pathways. The the Wnt/β-catenin and EGFR pathways activate each other. Binding of Wnt ligands with frizzled (FZD) receptors transactivates EGFR signaling by matrix metalloproteinase (MMP)-mediated release of soluble EGFR ligands. EGFR signaling transactivates Wnt/β-catenin signaling through the phosphoinositide 3-kinase (PI3K)/Akt and Ras/Raf/mitogen-activated protein kinase kinase (MEK)/extracellular-signal-regulated kinase (Erk) pathways but also by releasing β-catenin from β-catenin–E-cadherin complexes as a result of Tyr654 phosphorylation. Activated β-catenin forms heterodimers with EGFR and in turn promotes the EGFR pathway. On the other hand, Wnt signaling stimulates FGF signaling by inducing FGF18 and FGF20 ligand expression. In turn, the association of FGF19 with FGFR leads to the release of β-catenin from the β-catenin–E-cadherin complexes. FGF2 signaling inhibits glycogen synthase kinase 3β (GSK3β) activity through the PI3K/Akt and Ras/Raf/MEK/Erk pathways. Activated Src homology region 2 domain containing phosphatase 2 (SHP2) in the PI3K/Akt pathway and the Ras/Raf/MEK/Erk pathway dephosphorylates parafibromin, which acquires the ability to bind β-catenin stably, overriding the repression effect on CYCLIND1 and MYC expression and triggering downstream signaling

Similarly to the EGFR pathway, FGF-initiated signaling is a cardinal regulator of hepatocyte proliferation, differentiation, embryonic development, and organogenesis as well as hepatic tumorigenesis [126, 127]. Especially in chronic hepatitis C associated HCC, activation of FGF signaling is observed [128, 129] and increased FGF levels are associated with enhanced HCV replication and release of infectious particles [130]. Cross talk of Wnt and FGF pathways in HCV-related HCC is supported by observations that FGF signaling leads to the release of β-catenin from the β-catenin–E-cadherin complexes because of the phosphorylation of Tyr654 as described above. Furthermore, FGF2 increases expression of β-catenin messenger RNA, upregulates β-catenin nuclear translocation, and inactivates GSK3β [131], probably mediated through activation of the PI3K/Akt and Ras/Raf/MEK/ERK pathways. Conversely, Wnt/β-catenin signaling is able to activate FGF signaling by increasing FGF18 and FGF20 expression [132] (Fig. 3). Thus again, vicious interaction between Wnt/β-catenin signaling and FGF signaling appears to occur.

It has been reported that the Src homology region 2 domain containing phosphatase 2 (SHP-2) can be activated by HCV structural protein E2 [133]. Thus conceivably SHP-2 may be an effector of EGFR and FGF signaling in HCV-related HCC. Overexpression of SHP-2 promotes liver tumor cell growth and metastasis by coordinately activating not only the PI3K/Akt and Ras/Raf/MEK/ERK pathways [121] but also Wnt/β-catenin signaling [134]. The latter effect is due to tyrosine dephosphorylation of parafibromin (encoded by CDC73), acting as a tumor suppressor inhibiting CYCLIND1 and MYC, together with suppressor of variegation 3-9 homolog 1. As a result, parafibromin acquires the ability to bind β-catenin stably, overriding the repression effect and inducing the expression of Wnt target genes [134] (Fig. 3). Together, these results suggest that SHP-2 is one of the critical molecules whose expression is enhanced during early HCV infection and contributes to the later progression to final HCC, which needs further investigation.

Conclusion

As one of the important cascades involved in HCV-related HCC initiation and development, Wnt/β-catenin signaling is aberrantly activated by HCV viral core and NS5A proteins. In turn, stimulated Wnt/β-catenin signaling promotes progression of hepatitis C during inflammation and fibrosis, eventually promoting cirrhosis and HCC. This interaction is further aggravated by a vicious circle involving the EGFR and FGF pathways.

Notes

Acknowledgements

This research was sponsored by a China Scholarship Council PhD fellowship to Wenhui Wang (file no. 201306190123).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73.e1.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Alter HJ, Seeff LB. Recovery, persistance, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20(1):17–35.PubMedCrossRefGoogle Scholar
  3. 3.
    Pawlotsky J-M. Diagnostic tests for hepatitis C. J Hepatol. 1999;31:71–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Castello G, Scala S, Palmieri G, et al. HCV-related hepatocellular carcinoma: from chronic inflammation to cancer. Clin Immunol. 2010;134(3):237–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6(9):674–87.PubMedCrossRefGoogle Scholar
  6. 6.
    Ginès P, Cárdenas A, Arroyo V, et al. Management of cirrhosis and ascites. N Engl J Med. 2004;350(16):1646–54.PubMedCrossRefGoogle Scholar
  7. 7.
    Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. Hepatology. 1995;21(1):77–82.PubMedGoogle Scholar
  8. 8.
    Lau CC, Sun T, Ching AK, et al. Viral-human chimeric transcript predisposes risk to liver cancer development and progression. Cancer Cell. 2014;25(3):335–49.PubMedCrossRefGoogle Scholar
  9. 9.
    Jeong SW, Jang JY, Chung RT. Hepatitis C virus and hepatocarcinogenesis. Clin Mol Hepatol. 2012;18(4):347–56.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Qu B, Liu BR, Du YJ, et al. Wnt/β-catenin signaling pathway may regulate the expression of angiogenic growth factors in hepatocellular carcinoma. Oncol Lett. 2014;7(4):1175–8.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2012;13(1):11–26.CrossRefGoogle Scholar
  12. 12.
    Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5):387–98.PubMedCrossRefGoogle Scholar
  13. 13.
    Papkoff J, Brown AM, Varmus HE. The int-1 proto-oncogene products are glycoproteins that appear to enter the secretory pathway. Mol Cell Biol. 1987;7(11):3978–84.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Branda M, Wands JR. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology. 2006;43(5):891–902.PubMedCrossRefGoogle Scholar
  15. 15.
    Yuzugullu H, Benhaj K, Ozturk N, et al. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer. 2009;8:90.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    van Amerongen R, Mikels A, Nusse R. Alternative Wnt signaling is initiated by distinct receptors. Sci Signal. 2008;1(35):re9.PubMedGoogle Scholar
  17. 17.
    Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis–a look outside the nucleus. Science. 2000;287(5458):1606–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Dahmani R, Just P-A, Perret C. The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2011;35(11):709–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Hart M, Concordet JP, Lassot I, et al. The F-box protein β-TrCP associates with phosphorylated β-catenin and regulates its activity in the cell. Curr Biol. 1999;9(4):207–11.PubMedCrossRefGoogle Scholar
  20. 20.
    Sharma M, Jamieson C, Johnson M, et al. Specific armadillo repeat sequences facilitate β-catenin nuclear transport in live cells via direct binding to nucleoporins Nup62, Nup153, and RanBP2/Nup358. J Biol Chem. 2012;287(2):819–31.PubMedCrossRefGoogle Scholar
  21. 21.
    Ma L, Wei W, Chua M-S, So S. WNT/β-catenin pathway activation in hepatocellular carcinoma: a clinical perspective. Gastrointest Cancer. 2014;4:49–63.Google Scholar
  22. 22.
    de Lau W, Peng WC, Gros P, et al. The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength. Genes Dev. 2014;28(4):305–16.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Hao HX, Xie Y, Zhang Y, et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature. 2012;485(7397):195–200.PubMedCrossRefGoogle Scholar
  24. 24.
    de Lau W, Barker N, Low TY, et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature. 2011;476(7360):293–7.PubMedCrossRefGoogle Scholar
  25. 25.
    van Veelen W, Le NH, Helvensteijn W, et al. β-Catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis. Gut. 2011;60(9):1204–12.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of β-catenin. Curr Opin Genet Dev. 2006;16(1):51–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Brabletz T, Hlubek F, Spaderna S, et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and β-catenin. Cells Tissues Organs. 2005;179(1–2):56–65.PubMedCrossRefGoogle Scholar
  28. 28.
    Lilien J, Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of β-catenin. Curr Opin Cell Biol. 2005;17(5):459–65.PubMedCrossRefGoogle Scholar
  29. 29.
    Yook JI, Li XY, Ota I, et al. Wnt-dependent regulation of the E-cadherin repressor snail. J Biol Chem. 2005;280(12):11740–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Batlle E, Sancho E, Francí C, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000;2(2):84–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Zhou BP, Deng J, Xia W, et al. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial–mesenchymal transition. Nat Cell Biol. 2004;6(10):931–40.PubMedCrossRefGoogle Scholar
  32. 32.
    Buda A, Pignatelli M. E-cadherin and the cytoskeletal network in colorectal cancer development and metastasis. Cell Commun Adhes. 2011;18(6):133–43.PubMedCrossRefGoogle Scholar
  33. 33.
    Lyon C, Mill C, Tsaousi A, et al. Regulation of VSMC behavior by the cadherin-catenin complex. Front Biosci (Landmark Ed). 2010;16:644–57.CrossRefGoogle Scholar
  34. 34.
    Pennisi E. How a growth control path takes a wrong turn to cancer. Science. 1998;281(5382):1438–41.PubMedCrossRefGoogle Scholar
  35. 35.
    Bakker ER, Hoekstra E, Franken PF, et al. β-Catenin signaling dosage dictates tissue-specific tumor predisposition in Apc-driven cancer. Oncogene. 2013;32(38):4579–85.PubMedCrossRefGoogle Scholar
  36. 36.
    Albuquerque C, Bakker ER, van Veelen W, et al. Colorectal cancers choosing sides. Biochim Biophys Acta. 2011;1816(2):219–31.PubMedGoogle Scholar
  37. 37.
    Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2001;1(1):55–67.PubMedCrossRefGoogle Scholar
  38. 38.
    Bengochea A, De Souza MM, Lefrancois L, et al. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer. 2008;99(1):143–50.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Rebouissou S, Franconi A, Calderaro J, et al. Genotype-phenotype correlation of CTNNB1 mutations reveals different β-catenin activity associated with liver tumor progression. Hepatology. 2016;64(6):2047–61.Google Scholar
  40. 40.
    Hirotsu Y, Zheng TH, Amemiya K, et al. Targeted and exome sequencing identified somatic mutations in hepatocellular carcinoma. Hepatol Res. 2016;46(11):1145–51.Google Scholar
  41. 41.
    Schulze K, Imbeaud S, Letouze E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47(5):505–11.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Kan Z, Zheng H, Liu X, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 2013;23(9):1422–33.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Kitao A, Matsui O, Yoneda N, et al. Hepatocellular carcinoma with β-catenin mutation: imaging and pathologic characteristics. Radiology. 2015;275(3):708–17.PubMedCrossRefGoogle Scholar
  44. 44.
    Ding X, Yang Y, Han B, et al. Transcriptomic characterization of hepatocellular carcinoma with CTNNB1 mutation. PLoS One. 2014;9(5):e95307.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Tornesello ML, Buonaguro L, Tatangelo F, et al. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics. 2013;102(2):74–83.PubMedCrossRefGoogle Scholar
  46. 46.
    Cleary SP, Jeck WR, Zhao X, et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology. 2013;58(5):1693–702.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012;44(6):694–8.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Lachenmayer A, Alsinet C, Savic R, et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res. 2012;18(18):4997–5007.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Li M, Zhao H, Zhang X, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet. 2011;43(9):828–9.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Cieply B, Zeng G, Proverbs-Singh T, et al. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology. 2009;49(3):821–31.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Austinat M, Dunsch R, Wittekind C, et al. Correlation between β-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma. Mol Cancer. 2008;7:21.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Kim YD, Park CH, Kim HS, et al. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23(1):110–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Zucman-Rossi J, Benhamouche S, Godard C, et al. Differential effects of inactivated Axin1 and activated β-catenin mutations in human hepatocellular carcinomas. Oncogene. 2007;26(5):774–80.PubMedCrossRefGoogle Scholar
  54. 54.
    Boyault S, Rickman DS, de Reynies A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007;45(1):42–52.PubMedCrossRefGoogle Scholar
  55. 55.
    Zucman-Rossi J, Jeannot E, Van Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43(3):515–24.PubMedCrossRefGoogle Scholar
  56. 56.
    Park JY, Park WS, Nam SW, et al. Mutations of β-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int. 2005;25(1):70–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Ishizaki Y, Ikeda S, Fujimori M, et al. Immunohistochemical analysis and mutational analyses of β-catenin, Axin family and APC genes in hepatocellular carcinomas. Int J Oncol. 2004;24(5):1077–83.PubMedGoogle Scholar
  58. 58.
    Cui J, Zhou X, Liu Y, et al. Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes. J Gastroenterol Hepatol. 2003;18(3):280–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Edamoto Y, Hara A, Biernat W, et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer. 2003;106(3):334–41.PubMedCrossRefGoogle Scholar
  60. 60.
    Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 2002;21(31):4863–71.PubMedCrossRefGoogle Scholar
  61. 61.
    Wong CM, Fan ST, Ng IO. β-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer. 2001;92(1):136–45.PubMedCrossRefGoogle Scholar
  62. 62.
    Mao TL, Chu JS, Jeng YM, et al. Expression of mutant nuclear β-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol. 2001;193(1):95–101.PubMedCrossRefGoogle Scholar
  63. 63.
    Cui J, Zhou X, Liu Y, et al. Mutation and overexpression of the β-catenin gene may play an important role in primary hepatocellular carcinoma among Chinese people. J Cancer Res Clin Oncol. 2001;127(9):577–81.PubMedCrossRefGoogle Scholar
  64. 64.
    Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology. 2001;120(7):1763–73.PubMedCrossRefGoogle Scholar
  65. 65.
    Devereux TR, Stern MC, Flake GP, et al. CTNNB1 mutations and β-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1. Mol Carcinog. 2001;31(2):68–73.PubMedCrossRefGoogle Scholar
  66. 66.
    Hsu HC, Jeng YM, Mao TL, et al. β-Catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol. 2000;157(3):763–70.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 2000;24(3):245–50.PubMedCrossRefGoogle Scholar
  68. 68.
    Huang H, Fujii H, Sankila A, et al. β-Catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol. 1999;155(6):1795–801.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Legoix P, Bluteau O, Bayer J, et al. β-Catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene. 1999;18(27):4044–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Terris B, Pineau P, Bregeaud L, et al. Close correlation between β-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene. 1999;18(47):6583–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Kondo Y, Kanai Y, Sakamoto M, et al. Beta-catenin accumulation and mutation of exon 3 of the beta-catenin gene in hepatocellular carcinoma. Jpn J Cancer Res. 1999;90(12):1301–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Van Nhieu JT, Renard CA, Wei Y, et al. Nuclear accumulation of mutated β-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol. 1999;155(3):703–10.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Miyoshi Y, Iwao K, Nagasawa Y, et al. Activation of the β-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res. 1998;58(12):2524–7.PubMedGoogle Scholar
  74. 74.
    de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A. 1998;95(15):8847–51.PubMedCentralCrossRefGoogle Scholar
  75. 75.
    Pan Q, Peppelenbosch MP, Janssen HL, et al. Telaprevir/boceprevir era: from bench to bed and back. World J Gastroenterol. 2012;18(43):6183–8.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene. 2006;25(27):3834–47.PubMedCrossRefGoogle Scholar
  77. 77.
    Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31(4):339–46.PubMedCrossRefGoogle Scholar
  78. 78.
    Machida K, Cheng KT, Sung VM, et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A. 2004;101(12):4262–7.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Moradpour D, Penin F. Hepatitis C virus proteins: from structure to function. In: Bartenschlager R, editor. Hepatitis C virus: from molecular virology to antiviral therapy. Berlin: Springer; 2013. p. 113–42.Google Scholar
  80. 80.
    McLauchlan J. Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. J Viral Hepatitis. 2000;7(1):2–14.CrossRefGoogle Scholar
  81. 81.
    Ray RB, Ray R. Hepatitis C virus core protein: intriguing properties and functional relevance. FEMS Microbiol Lett. 2001;202(2):149–56.PubMedCrossRefGoogle Scholar
  82. 82.
    Fukutomi T, Zhou Y, Kawai S, et al. Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology. 2005;41(5):1096–105.PubMedCrossRefGoogle Scholar
  83. 83.
    Liu J, Ding X, Tang J, et al. Enhancement of canonical Wnt/β-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells. PLoS One. 2011;6(11):e27496.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Umer M, Qureshi SA, Hashmi ZY, et al. Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus-induced multistep hepatocarcinogenesis. Virol J. 2014;11(1):117.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Quan H, Zhou F, Nie D, et al. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial–mesenchymal transition. Oncogene. 2014;33(22):2826–35.PubMedCrossRefGoogle Scholar
  86. 86.
    Ripoli M, Barbano R, Balsamo T, et al. Hypermethylated levels of E-cadherin promoter in Huh-7 cells expressing the HCV core protein. Virus Res. 2011;160(1):74–81.PubMedCrossRefGoogle Scholar
  87. 87.
    Gosert R, Egger D, Lohmann V, et al. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol. 2003;77(9):5487–92.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Street A, Macdonald A, Crowder K, et al. The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J Biol Chem. 2004;279(13):12232–41.PubMedCrossRefGoogle Scholar
  89. 89.
    Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol. 2004;85(9):2485–502.PubMedCrossRefGoogle Scholar
  90. 90.
    Street A, Macdonald A, McCormick C, et al. Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular β-catenin and stimulation of β-catenin-responsive transcription. J Virol. 2005;79(8):5006–16.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Park CY, Choi SH, Kang SM, et al. Nonstructural 5A protein activates β-catenin signaling cascades: implication of hepatitis C virus-induced liver pathogenesis. J Hepatol. 2009;51(5):853–64.PubMedCrossRefGoogle Scholar
  92. 92.
    Milward A, Mankouri J, Harris M. Hepatitis C virus NS5A protein interacts with β-catenin and stimulates its transcriptional activity in a phosphoinositide-3 kinase-dependent fashion. J Gen Virol. 2010;91:373–81.PubMedCrossRefGoogle Scholar
  93. 93.
    Zhang Y, Wei W, Cheng N, et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology. 2012;56(5):1631–40.PubMedCrossRefGoogle Scholar
  94. 94.
    Wang H, Gao H, Duan S, et al. Inhibition of microRNA-199a-5p reduces the replication of HCV via regulating the pro-survival pathway. Virus Res. 2015;208:7–12.PubMedCrossRefGoogle Scholar
  95. 95.
    Jiang S, Zhang H-W, Lu M-H, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010;70(8):3119–27.PubMedCrossRefGoogle Scholar
  96. 96.
    Sun H, Yu L, Wei H, et al. A novel antihepatitis drug, bicyclol, prevents liver carcinogenesis in diethylnitrosamine-initiated and phenobarbital-promoted mice tumor model. J Biomed Biotechnol. 2012;2012:584728.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Sivaramakrishnan V, Shilpa PN, Praveen Kumar VR, et al. Attenuation of N-nitrosodiethylamine-induced hepatocellular carcinogenesis by a novel flavonol—morin. Chem Biol Interact. 2008;171(1):79–88.PubMedCrossRefGoogle Scholar
  98. 98.
    Reuter S, Martin H, Beckert H, et al. The Wnt/β-catenin pathway attenuates experimental allergic airway disease. J Immunol. 2014;193(2):485–95.PubMedCrossRefGoogle Scholar
  99. 99.
    Trischler J, Shiomi T, Turner DL, et al. Immune modulation of the T cell response in asthma through Wnt10b. Am J Respir Cell Mol Biol. 2016;54(4):584–93.Google Scholar
  100. 100.
    Neumann J, Schaale K, Farhat K, et al. Frizzled1 is a marker of inflammatory macrophages, and its ligand Wnt3a is involved in reprogramming Mycobacterium tuberculosis-infected macrophages. FASEB J. 2010;24(11):4599–612.PubMedCrossRefGoogle Scholar
  101. 101.
    Anson M, Crain-Denoyelle A-M, Baud V, et al. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Investig. 2012;122(2):586.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Liu Y, El-Serag HB, Jiao L, et al. WNT signaling pathway gene polymorphisms and risk of hepatic fibrosis and inflammation in HCV-infected patients. PLoS One. 2013;8(12):84407.CrossRefGoogle Scholar
  103. 103.
    Takahara Y, Takahashi M, Zhang Q-W, et al. Serial changes in expression of functionally clustered genes in progression of liver fibrosis in hepatitis C patients. World J Gastroenterol. 2008;14(13):2010.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Monga SP. β-Catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology. 2015;148(7):1294–310.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Gusterson BA, Hunter KD. Should we be surprised at the paucity of response to EGFR inhibitors? Lancet Oncol. 2009;10(5):522–7.PubMedCrossRefGoogle Scholar
  106. 106.
    Carver RS, Stevenson MC, Scheving LA, et al. Diverse expression of ErbB receptor proteins during rat liver development and regeneration. Gastroenterology. 2002;123(6):2017–27.PubMedCrossRefGoogle Scholar
  107. 107.
    Collin de l’Hortet A, Gilgenkrantz H, Guidotti J-E. EGFR: a master piece in G1/S phase transition of liver regeneration. Int J Hepatol. 2012;2012:476910.Google Scholar
  108. 108.
    Berasain C, Castillo J, Prieto J, et al. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int. 2007;27(2):174–85.PubMedCrossRefGoogle Scholar
  109. 109.
    Berasain C, Perugorria MJ, Latasa MU, et al. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med. 2009;234(7):713–25.CrossRefGoogle Scholar
  110. 110.
    Peschard P, Park M. Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell. 2003;3(6):519–23.PubMedCrossRefGoogle Scholar
  111. 111.
    Meyer K, Kwon Y-C, Liu S, et al. Interferon-α inducible protein 6 impairs EGFR activation by CD81 and inhibits hepatitis C virus infection. Sci Rep. 2015;5;9012.Google Scholar
  112. 112.
    Diao J, Pantua H, Ngu H, et al. Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J Virol. 2012;86(20):10935–49.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Zheng K, Kitazato K, Wang Y. Viruses exploit the function of epidermal growth factor receptor. Rev Med Virol. 2014;24(4):274–86.PubMedCrossRefGoogle Scholar
  114. 114.
    Igloi Z, Kazlauskas A, Saksela K, et al. The hepatitis C virus NS5A protein blocks EGFR degradation via a proline motif dependent interaction. J Gen Virol. 2015;96(8):2133–44.CrossRefGoogle Scholar
  115. 115.
    Civenni G, Holbro T, Hynes NE. Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO Rep. 2003;4(2):166–71.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Hu T, Li C. Convergence between Wnt-β-catenin and EGFR signaling in cancer. Mol Cancer. 2010;9:236.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Roura S, Miravet S, Piedra J, et al. Regulation of E-cadherin/catenin association by tyrosine phosphorylation. J Biol Chem. 1999;274(51):36734–40.PubMedCrossRefGoogle Scholar
  118. 118.
    Monga SP, Mars WM, Pediaditakis P, et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of β-catenin after Met-β-catenin dissociation in hepatocytes. Cancer Res. 2002;62(7):2064–71.PubMedGoogle Scholar
  119. 119.
    Zeng G, Apte U, Micsenyi A, et al. Tyrosine residues 654 and 670 in β-catenin are crucial in regulation of Met-β-catenin interactions. Exp Cell Res. 2006;312(18):3620–30.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Pai R, Dunlap D, Qing J, et al. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating β-catenin signaling. Cancer Res. 2008;68(13):5086–95.PubMedCrossRefGoogle Scholar
  121. 121.
    Han T, Xiang D-M, Sun W, et al. PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients. J Hepatol. 2015;63(3):651–60.PubMedCrossRefGoogle Scholar
  122. 122.
    Kim D, Rath O, Kolch W, et al. A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK pathways. Oncogene. 2007;26(31):4571–9.PubMedCrossRefGoogle Scholar
  123. 123.
    Lu Z, Ghosh S, Wang Z, et al. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of β-catenin, and enhanced tumor cell invasion. Cancer Cell. 2003;4(6):499–515.PubMedCrossRefGoogle Scholar
  124. 124.
    Ji H, Wang J, Nika H, et al. EGF-induced ERK activation promotes CK2-mediated disassociation of α-catenin from β-catenin and transactivation of β-catenin. Mol Cell. 2009;36(4):547–59.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Sharma M, Chuang WW, Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation. J Biol Chem. 2002;277(34):30935–41.PubMedCrossRefGoogle Scholar
  126. 126.
    Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8(3):235–53.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Gauglhofer C, Sagmeister S, Schrottmaier W, et al. Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology. 2011;53(3):854–64.PubMedCrossRefGoogle Scholar
  128. 128.
    Guimei M, Baddour N, ElKaffash D, et al. Gremlin in the pathogenesis of hepatocellular carcinoma complicating chronic hepatitis C: an immunohistochemical and PCR study of human liver biopsies. BMC Res Notes. 2012;5(1):390.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Sawey ET, Chanrion M, Cai C, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell. 2011;19(3):347–58.PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    Van ND, Falk CS, Vondran FW, et al. Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators. Gut. 2016;65(6):1015–23.PubMedCrossRefGoogle Scholar
  131. 131.
    Israsena N, Hu M, Fu W, et al. The presence of FGF2 signaling determines whether β-catenin exerts effects on proliferation or neuronal differentiation of neural stem cells. Dev Biol. 2004;268(1):220–31.PubMedCrossRefGoogle Scholar
  132. 132.
    Katoh M, Katoh M. Review cross-talk of WNT and FGF signaling pathways at GSK3β to regulate β-catenin and SNAIL signaling cascades. Cancer Biol Ther. 2006;5:1059–64.PubMedCrossRefGoogle Scholar
  133. 133.
    Balasubramanian A, Ganju RK, Groopman JE. Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes. J Biol Chem. 2003;278(37):35755–66.PubMedCrossRefGoogle Scholar
  134. 134.
    Takahashi A, Tsutsumi R, Kikuchi I, et al. SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver. Mol Cell. 2011;43(1):45–56.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© The Author(s) 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Wenhui Wang
    • 1
  • Qiuwei Pan
    • 1
  • Gwenny M. Fuhler
    • 1
  • Ron Smits
    • 1
  • Maikel P. Peppelenbosch
    • 1
  1. 1.Department of Gastroenterology and HepatologyErasmus University Medical CenterRotterdamNetherlands

Personalised recommendations